Literature DB >> 1456279

Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature.

C L Garganta1, J N Bodurtha.   

Abstract

Simpson-Golabi-Behmel Syndrome (SGBS), an X-linked encephalo-tropho-schisis syndrome described in fewer than a dozen families, is characterized by pre- and postnatal overgrowth, "coarse" face, minor facial anomalies and, in more severe cases, multiple congenital anomalies and mental retardation. We report on 2 brothers with overgrowth, macrocephaly, polydactyly, supernumerary nipples, and characteristic facial appearance. In addition, the propositus also had pulmonic stenosis and a cleft palate. The findings present in our patients are compared to those in the original patients and to those in patients described more recently. Despite the fact that our patients have most of the minor and several of the more severe malformations, they are not mentally retarded.

Entities:  

Mesh:

Year:  1992        PMID: 1456279     DOI: 10.1002/ajmg.1320440202

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  11 in total

Review 1.  Glypicans: proteoglycans with a surprise.

Authors:  J Filmus; S B Selleck
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 2.  The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans.

Authors:  Jorge Filmus
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

3.  Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes.

Authors:  J Eggenschwiler; T Ludwig; P Fisher; P A Leighton; S M Tilghman; A Efstratiadis
Journal:  Genes Dev       Date:  1997-12-01       Impact factor: 11.361

4.  A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma.

Authors:  P Lapunzina; I Badia; C Galoppo; E De Matteo; P Silberman; A Tello; J Grichener; R Hughes-Benzie
Journal:  J Med Genet       Date:  1998-02       Impact factor: 6.318

5.  Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome.

Authors:  Zhi-Xing Yao; Wilma Jogunoori; Sanaa Choufani; Asif Rashid; Tiffany Blake; Wenguo Yao; Peter Kreishman; Rupen Amin; Anton A Sidawy; Stephen R T Evans; Milton Finegold; E Premkumar Reddy; Bibhuti Mishra; Rosanna Weksberg; Rakesh Kumar; Lopa Mishra
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

6.  Evaluation of asymmetric immunoliposomal nanoparticles for cellular uptake.

Authors:  Jeremiah Whittenton; Ramanan Pitchumani; Sundararajah Thevananther; Kishore Mohanty
Journal:  J Microencapsul       Date:  2012-06-28       Impact factor: 3.142

7.  Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome.

Authors:  D F Cano-Gauci; H H Song; H Yang; C McKerlie; B Choo; W Shi; R Pullano; T D Piscione; S Grisaru; S Soon; L Sedlackova; A K Tanswell; T W Mak; H Yeger; G A Lockwood; N D Rosenblum; J Filmus
Journal:  J Cell Biol       Date:  1999-07-12       Impact factor: 10.539

Review 8.  Tall stature: a difficult diagnosis?

Authors:  Cristina Meazza; Chiara Gertosio; Roberta Giacchero; Sara Pagani; Mauro Bozzola
Journal:  Ital J Pediatr       Date:  2017-08-03       Impact factor: 2.638

9.  SGBS cells as a model of human adipocyte browning: A comprehensive comparative study with primary human white subcutaneous adipocytes.

Authors:  Chia Rou Yeo; Madhur Agrawal; Shawn Hoon; Asim Shabbir; Manu Kunaal Shrivastava; Shiqi Huang; Chin Meng Khoo; Vanna Chhay; M Shabeer Yassin; E Shyong Tai; Antonio Vidal-Puig; Sue-Anne Toh
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

10.  OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner.

Authors:  A D Gonzalez; M Kaya; W Shi; H Song; J R Testa; L Z Penn; J Filmus
Journal:  J Cell Biol       Date:  1998-06-15       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.